AR040797A1 - Formulaciones para la disfuncion sexual y usos de las mismas - Google Patents
Formulaciones para la disfuncion sexual y usos de las mismasInfo
- Publication number
- AR040797A1 AR040797A1 AR20030102814A ARP030102814A AR040797A1 AR 040797 A1 AR040797 A1 AR 040797A1 AR 20030102814 A AR20030102814 A AR 20030102814A AR P030102814 A ARP030102814 A AR P030102814A AR 040797 A1 AR040797 A1 AR 040797A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- acceptable
- sexual dysfunction
- pharmaceutical use
- compound selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Confectionery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica de inicio rápido que contiene un compuesto para la disfunción sexual que comprende polvo de cacao, un proceso para la fabricación de la composición y el uso de la composición en la terapia de la disfunción sexual. Reivindicación 4: Una composición de acuerdo con cualquier reivindicación precedente, caracterizado porque los compuestos para la disfunción sexual se seleccionan entre los siguientes compuestos: un compuesto de fórmula (1) o una sal del mismo aceptable para uso farmacéutico, donde R1, R2 y R3 son iguales o diferentes, y son H, alquilo C1-6 (opcionalmente sustituido con fenilo), alquenilo C3-5 o alquinilo, o cicloalquilo C3-10, o R3 es como se mencionó previamente y R1 y R2 se ciclan con el átomo de N adjunto para formar grupo pirrolidinilo, piperidinilo, morfolinilo, 4-metilpiperazinilo o imidazolilo; X es H, F, Cl, Br, I, OH, alquilo C1-6 o alcoxilo, CN, carboxamida, carboxil o (alquil C1-6)carbonilo; A es CH, CH2, CHF, CHCl, CHBr, CHI, CHCH3, C=O, C=S, CSCH3, C=NH, CNH2, CNHCH3, CNHCOOH3, CNHCN, SO2 o N; B es CH, CH2, CHF, CHCl, CHBr, CHI, C=O, N, NH o NCH3, y n es 0 ó 1; y D es CH, CH2, CHF, CHCl, CHBr, CHI, C=O, o, N, NH o NCH3; donde dicho compuesto de fórmula (1), o dicha sal del mismo, es soluble en agua; un compuesto de fórmula (2) donde X es O o S, y sales del mismo aceptables para uso farmacéutico; un compuesto seleccionado entre inhibidores de la fosfodiesterasa tipo 5 (PDE5), tales como sildenfil en forma de base, y sales del mismos aceptables para uso farmacéutico, incluyendo citrato de sildenafil, vardenafil y tadalafil; un compuesto seleccionado entre agonistas dopaminérgicos, tales como apomorfina, opcionalmente con la condición de agentes anti-eméticos; un compuesto seleccionado entre antagonistas alfa noradrenérgicos o antagonistas alfa-adrenérgicos, tales como mesilato de fentolamina, yohimbina y prazosina; un compuesto seleccionado entre actividades del AMP cíclico; y sales, complejos y mezclas de los mismos aceptables para el uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202365A SE0202365D0 (sv) | 2002-08-05 | 2002-08-05 | New formulation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040797A1 true AR040797A1 (es) | 2005-04-20 |
Family
ID=20288677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102814A AR040797A1 (es) | 2002-08-05 | 2003-08-05 | Formulaciones para la disfuncion sexual y usos de las mismas |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1539096A1 (es) |
| JP (1) | JP2005539008A (es) |
| CN (1) | CN1674866B (es) |
| AR (1) | AR040797A1 (es) |
| AU (1) | AU2003239038B2 (es) |
| BR (1) | BR0313224A (es) |
| CA (1) | CA2495527C (es) |
| IL (1) | IL166031A0 (es) |
| MX (1) | MXPA05000978A (es) |
| NZ (1) | NZ537520A (es) |
| RU (1) | RU2312665C2 (es) |
| SE (1) | SE0202365D0 (es) |
| TW (1) | TW200418470A (es) |
| WO (1) | WO2004012702A1 (es) |
| ZA (1) | ZA200500051B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10232113A1 (de) | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
| DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
| DE102005009240A1 (de) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| DE102010024866A1 (de) * | 2010-06-24 | 2011-12-29 | Pharmatech Gmbh | Formulierung zur Geschmacksmaskierung |
| EP3299010B1 (de) | 2016-09-21 | 2022-11-09 | LTS Lohmann Therapie-Systeme AG | Orale darreichungsform |
| BR112020017468A2 (pt) | 2018-03-01 | 2020-12-22 | Lts Lohmann Therapie-Systeme Ag | Forma de dosagem oral com cacau livre de teobromina |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4755180A (en) * | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
| FR2717387B1 (fr) * | 1994-03-17 | 1996-10-18 | Hi Pharmtech | Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline. |
| US6121276A (en) | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| ES2105970B1 (es) * | 1995-08-02 | 1998-07-01 | S A L V A T Lab Sa | Composicion farmaceutica oral de ciprofloxacino, no acuosa, estable y con caracteristicas organolepticas mejoradas. |
| CA2178021C (en) * | 1996-04-19 | 1999-09-28 | Theodore H. Stanley | Tobacco substitute |
| ID21806A (id) * | 1997-01-06 | 1999-07-29 | Pfizer | Bentuk penakaran farmasi yang secara cepat dilepaskan dan yang menutup rasa |
| GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
| JP2000095710A (ja) * | 1998-09-21 | 2000-04-04 | Taisho Pharmaceut Co Ltd | カカオ末を配合した経口用固形製剤 |
| JP2000119198A (ja) * | 1998-10-16 | 2000-04-25 | Eisai Co Ltd | 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤 |
| US6060094A (en) * | 1998-10-30 | 2000-05-09 | Nestec S.A. | Method of reducing fat in fat-based coating for confectionery products |
| SE9803986D0 (sv) | 1998-11-23 | 1998-11-23 | Pharmacia & Upjohn Ab | New compositions |
| US6531114B1 (en) * | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US6291471B1 (en) | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
| US6455564B1 (en) * | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| JP2003506394A (ja) | 1999-08-10 | 2003-02-18 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法 |
| JP2001114668A (ja) * | 1999-10-13 | 2001-04-24 | Meiji Seika Kaisha Ltd | チョコレート剤 |
| BR0012822A (pt) | 1999-12-30 | 2004-03-09 | Tap Holdings Inc | Formulação farmacêutica, e, forma de dosagem em tablete |
| AU2001273545A1 (en) | 2000-07-19 | 2002-01-30 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
| JP2002193839A (ja) * | 2000-12-27 | 2002-07-10 | Meiji Seika Kaisha Ltd | ココア製剤 |
| JP2004520389A (ja) * | 2001-02-08 | 2004-07-08 | ファルマシア・コーポレーション | 性的不全の治療のための早期効果発現薬剤 |
| US20020172732A1 (en) * | 2001-03-21 | 2002-11-21 | Wies Ter Laak | Composition comprising cocoa |
-
2002
- 2002-08-05 SE SE0202365A patent/SE0202365D0/xx unknown
-
2003
- 2003-06-18 NZ NZ537520A patent/NZ537520A/en not_active IP Right Cessation
- 2003-06-18 BR BR0313224-2A patent/BR0313224A/pt not_active Application Discontinuation
- 2003-06-18 EP EP03733755A patent/EP1539096A1/en not_active Ceased
- 2003-06-18 CN CN038188910A patent/CN1674866B/zh not_active Expired - Fee Related
- 2003-06-18 WO PCT/SE2003/001022 patent/WO2004012702A1/en active Application Filing
- 2003-06-18 CA CA002495527A patent/CA2495527C/en not_active Expired - Fee Related
- 2003-06-18 MX MXPA05000978A patent/MXPA05000978A/es active IP Right Grant
- 2003-06-18 AU AU2003239038A patent/AU2003239038B2/en not_active Ceased
- 2003-06-18 JP JP2004525901A patent/JP2005539008A/ja active Pending
- 2003-06-18 RU RU2005102835/15A patent/RU2312665C2/ru not_active IP Right Cessation
- 2003-07-25 TW TW092120418A patent/TW200418470A/zh unknown
- 2003-08-05 AR AR20030102814A patent/AR040797A1/es not_active Application Discontinuation
-
2004
- 2004-12-28 IL IL16603104A patent/IL166031A0/xx unknown
-
2005
- 2005-01-04 ZA ZA2005/00051A patent/ZA200500051B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005102835A (ru) | 2005-08-10 |
| CA2495527C (en) | 2008-12-30 |
| AU2003239038B2 (en) | 2008-01-03 |
| BR0313224A (pt) | 2005-07-05 |
| MXPA05000978A (es) | 2005-12-12 |
| JP2005539008A (ja) | 2005-12-22 |
| SE0202365D0 (sv) | 2002-08-05 |
| CN1674866A (zh) | 2005-09-28 |
| RU2312665C2 (ru) | 2007-12-20 |
| EP1539096A1 (en) | 2005-06-15 |
| AU2003239038A1 (en) | 2004-02-23 |
| IL166031A0 (en) | 2006-01-15 |
| ZA200500051B (en) | 2006-12-27 |
| WO2004012702A1 (en) | 2004-02-12 |
| NZ537520A (en) | 2006-11-30 |
| TW200418470A (en) | 2004-10-01 |
| CN1674866B (zh) | 2012-09-26 |
| CA2495527A1 (en) | 2004-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| MXPA04003474A (es) | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a. | |
| AR015595A1 (es) | Compuestos derivados de pirazolo [4,3-d]-pirimidin-7-onas, composiciones farmaceuticas, formulacion veterinaria, uso de dichos compuestos en la preparacionde composicion y formulaciones. procedimientos para su uso, compuestos intermediarios, proceso para la preparacion de los compuestos. | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| PE20070004A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
| AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| PE20020062A1 (es) | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a | |
| PE20100737A1 (es) | Nuevos compuestos | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| PE20211703A1 (es) | Compuesto derivado heterotriciclico novedoso y uso del mismo | |
| UA95223C2 (ru) | Производные пиридопиримидина, их получение, их применение в терапии | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| AR003976A1 (es) | Un compuesto derivado de pirazol, un procedimiento para producirlo, uso del mismo, una formulacion parasiticida veterinaria y una formulacion farmaceutica que comprenden dicho compuesto derivado y un procedimiento para tratar una infestacion por parasitos en un lugar | |
| AR038401A1 (es) | Derivados de indazol substituidos como agentes terapeuticos | |
| RU2006108799A (ru) | N3-замещенные имидазопиридиновые ингибиторы c-kit | |
| JP2014511898A5 (es) | ||
| PA8589601A1 (es) | Derivados de indazol como antagonistas del crf | |
| AR018915A1 (es) | Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos | |
| AR040797A1 (es) | Formulaciones para la disfuncion sexual y usos de las mismas | |
| SE0101579D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |